https://www.selleckchem.com/pr....oducts/derazantinib.
ed light on pathologic processes underlying psychosis in primary psychiatric disorders. © Copyright 2020 Physicians Postgraduate Press, Inc.BACKGROUND Psychiatric patients are known to be at high risk of developing cardiovascular diseases (CVDs), leading to an increased mortality rate. OBJECTIVE To assess the CVD risk (presence of metabolic syndrome [MetS] and calculated 10-year CVD risk) in a Swiss psychiatric cohort taking weight gain-inducing psychotropic drugs, compare the findings to a Swiss population-based cohort, and evalua
Like
Comment
Share
